Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.580
+0.010 (0.39%)
Mar 10, 2026, 4:00 PM EDT - Market closed
Annovis Bio Employees
As of December 31, 2024, Annovis Bio had 15 total employees, including 8 full-time and 7 part-time employees. The number of employees decreased by 1 or -6.25% compared to the previous year.
Employees
15
Change (1Y)
-1
Growth (1Y)
-6.25%
Revenue / Employee
n/a
Profits / Employee
-$1,658,963
Market Cap
68.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| XBiotech | 88 |
| InflaRx | 74 |
| Mereo BioPharma Group | 36 |
| Q32 Bio | 26 |
| MediciNova | 13 |
| Cingulate | 13 |
| Actuate Therapeutics | 10 |
ANVS News
- 7 days ago - Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - GlobeNewsWire
- 26 days ago - Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients - GlobeNewsWire
- 3 months ago - Annovis to Host Corporate Update Webinar on January 28, 2026 - GlobeNewsWire
- 3 months ago - Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group - GlobeNewsWire
- 3 months ago - Annovis Announces Two Presentations at the CTAD 2025 Conference - GlobeNewsWire
- 4 months ago - Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study - GlobeNewsWire
- 4 months ago - Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients - Benzinga